Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Amarin
Deal Size : Undisclosed
Deal Type : Collaboration
Amarin Supports Investigator-Initiated Trial at Kaiser
Details : Study aims to evaluate effects of icosapent ethyl (VASCEPA®) (IPE) on laboratory-confirmed viral upper respiratory infection (URI) rates, clinical impact and outcomes, especially with SARS-CoV-2 infection in adults with established atherosclerotic cardi...
Product Name : Vascepa
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 08, 2020
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Amarin
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Civica Rx
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Kaiser Permanente to join as a governing member with the goal of helping to secure supplies of essential generic medications during COVID-19 and beyond.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 22, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Civica Rx
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : TAK-919
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NIH clinical trial of investigational vaccine for COVID-19 begins
Details : Researchers at Kaiser Permanente Washington Health Research Institute (KPWHRI) have launched Phase I testing of an investigational vaccine against coronavirus.
Product Name : mRNA-1273
Product Type : Vaccine
Upfront Cash : Inapplicable
March 17, 2020
Lead Product(s) : TAK-919
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable